| Foot & Ankle Clinics Pa | |
|
563 Bielenberg Dr, Suite 150, Woodbury, MN 55125-4425 | |
| (218) 365-2570 | |
| (218) 365-2570 |
| Full Name | Foot & Ankle Clinics Pa |
|---|---|
| Type | Facility |
| Speciality | Podiatrist |
| Location | 563 Bielenberg Dr, Woodbury, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801836234 | NPI | - | NPPES |
| 43240800 | Medicaid | WI | |
| 944325800 | Medicaid | MN | |
| 43214500 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 473 (Minnesota) | Primary |
| Provider Name | Jeffrey Craig Pellersels |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1790730380 PECOS PAC ID: 7517860844 Enrollment ID: I20050913000958 |
News Archive
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of its SMARTer Ultra Low RNA Kit for Illumina Sequencing, which was developed in collaboration with Illumina, Inc.
A novel intraoperative bone wedge resection technique for Dwyer calcaneal osteotomy to correct calcaneal varus deformity is simple, accurate, and reproducible, restoring normal tibia calcaneal alignment, concludes a team of US investigators.
An inexpensive, routine blood test could hold the key to why some patients with congestive heart failure do well after being discharged from the hospital and why others risk relapse, costly readmission or death within a year, new Johns Hopkins research suggests.
In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
› Verified 3 days ago
| Provider Name | Dirk S Halverson |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1518958925 PECOS PAC ID: 2567488950 Enrollment ID: I20051102000652 |
News Archive
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of its SMARTer Ultra Low RNA Kit for Illumina Sequencing, which was developed in collaboration with Illumina, Inc.
A novel intraoperative bone wedge resection technique for Dwyer calcaneal osteotomy to correct calcaneal varus deformity is simple, accurate, and reproducible, restoring normal tibia calcaneal alignment, concludes a team of US investigators.
An inexpensive, routine blood test could hold the key to why some patients with congestive heart failure do well after being discharged from the hospital and why others risk relapse, costly readmission or death within a year, new Johns Hopkins research suggests.
In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
› Verified 3 days ago
| Provider Name | Guy J Werkhoven |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1942288980 PECOS PAC ID: 0840201984 Enrollment ID: I20060605000218 |
News Archive
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of its SMARTer Ultra Low RNA Kit for Illumina Sequencing, which was developed in collaboration with Illumina, Inc.
A novel intraoperative bone wedge resection technique for Dwyer calcaneal osteotomy to correct calcaneal varus deformity is simple, accurate, and reproducible, restoring normal tibia calcaneal alignment, concludes a team of US investigators.
An inexpensive, routine blood test could hold the key to why some patients with congestive heart failure do well after being discharged from the hospital and why others risk relapse, costly readmission or death within a year, new Johns Hopkins research suggests.
In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
› Verified 3 days ago
| Provider Name | Roy R Moeller |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1225027378 PECOS PAC ID: 3476566043 Enrollment ID: I20080119000002 |
News Archive
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of its SMARTer Ultra Low RNA Kit for Illumina Sequencing, which was developed in collaboration with Illumina, Inc.
A novel intraoperative bone wedge resection technique for Dwyer calcaneal osteotomy to correct calcaneal varus deformity is simple, accurate, and reproducible, restoring normal tibia calcaneal alignment, concludes a team of US investigators.
An inexpensive, routine blood test could hold the key to why some patients with congestive heart failure do well after being discharged from the hospital and why others risk relapse, costly readmission or death within a year, new Johns Hopkins research suggests.
In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
› Verified 3 days ago
| Provider Name | Carly Lucille Kriedberg |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1275972259 PECOS PAC ID: 7416248943 Enrollment ID: I20170830000513 |
News Archive
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of its SMARTer Ultra Low RNA Kit for Illumina Sequencing, which was developed in collaboration with Illumina, Inc.
A novel intraoperative bone wedge resection technique for Dwyer calcaneal osteotomy to correct calcaneal varus deformity is simple, accurate, and reproducible, restoring normal tibia calcaneal alignment, concludes a team of US investigators.
An inexpensive, routine blood test could hold the key to why some patients with congestive heart failure do well after being discharged from the hospital and why others risk relapse, costly readmission or death within a year, new Johns Hopkins research suggests.
In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Foot & Ankle Clinics Pa 563 Bielenberg Dr, Suite 150, Woodbury, MN 55125-4425 Ph: (218) 365-2570 | Foot & Ankle Clinics Pa 563 Bielenberg Dr, Suite 150, Woodbury, MN 55125-4425 Ph: (218) 365-2570 |
News Archive
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of its SMARTer Ultra Low RNA Kit for Illumina Sequencing, which was developed in collaboration with Illumina, Inc.
A novel intraoperative bone wedge resection technique for Dwyer calcaneal osteotomy to correct calcaneal varus deformity is simple, accurate, and reproducible, restoring normal tibia calcaneal alignment, concludes a team of US investigators.
An inexpensive, routine blood test could hold the key to why some patients with congestive heart failure do well after being discharged from the hospital and why others risk relapse, costly readmission or death within a year, new Johns Hopkins research suggests.
In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
› Verified 3 days ago
Jeffrey Craig Pellersels, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 563 Bielenberg Dr, Suite 150, Woodbury, MN 55125 Phone: 651-457-4665 Fax: 651-457-3115 |